Enfortumab vedotin

EV-103/KEYNOTE-869

Enfortumab vedotin EV-103/KEYNOTE-869

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ORR

ADJUSTMENTS

Quality of life

Serious and disabling adverse effects

>30% grade 3-4 toxicities impacting well being

Other adjustments

Enfortumab vedotin EV-103/KEYNOTE-869

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

2

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: For patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
Experimental Arm: Enfortumab vedotin + Pembrolizumab
Control Arm: Single arm